CompletedEUCTR 2017-000918-36

A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolarity type I

This historical record does not confirm current site availability.

Historical research recordMultiple countries

The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Austria · Bulgaria and 4 more locations
Study phase: Phase 3

Get this study by email

Study clarity

Study information

Study start dateNot clearly listed

Recruitment status: Completed
Enrollment listed in the registry: 500
Sponsor: Alkermes Inc
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Austria, Bulgaria, Ireland, ...
Age range: Not clearly listed
Official registry ID: EUCTR 2017-000918-36
Official title: Show the full official title
A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Austria · Bulgaria · Ireland

3 more locations

Italy
Romania
Spain

Registry details

Historical country statuses

Austria — Completed
Bulgaria — Completed
Spain — Completed
Ireland — Completed
Italy — Completed
Romania — Completed

Interested in joining this study?

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Alkermes Inc.

Want to explore more studies?

Explore studies